速递｜MASH治疗新基石！司美格鲁肽获AASLD指南推荐

Core Viewpoint - The article discusses the recent advancements in the treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) using semaglutide, highlighting its FDA approval and the positive outcomes from clinical trials [6][7][9]. Group 1: Clinical Guidelines and Recommendations - The latest practice guidelines published in HEPATOLOGY focus on the application of semaglutide in treating MASH, particularly for patients with moderate to advanced fibrosis (F2-F3 stages) [6]. - The guidelines integrate recent trial data, including the ESSENCE study, and provide actionable recommendations for clinical teams [6][9]. - Experts emphasize the rapid advancement in MASH research and the need for evidence-based treatment options to ensure patient safety and efficacy monitoring [6][9]. Group 2: FDA Approvals and Market Position - In June, Novo Nordisk announced that the FDA granted accelerated approval for its weight loss drug Wegovy for treating MASH, solidifying its position in the metabolic disease sector [6]. - Prior to this, the only FDA-approved MASH treatment was Madrigal Pharmaceuticals' Rezdiffra, which received approval in 2024 based on early results from an ongoing two-phase study [7]. Group 3: Clinical Trial Results - The ESSENCE study's first major endpoint showed that 62.9% of patients treated with 2.4 mg of semaglutide experienced resolution of steatohepatitis without worsening fibrosis, compared to 34.3% in the placebo group, indicating a significant difference of 28.7% [8]. - For the second major endpoint, 36.8% of the semaglutide group showed improvement in fibrosis without worsening steatosis, versus 22.4% in the placebo group, with a difference of 14.4% [8]. - The study's secondary endpoint revealed that 32.7% of patients on semaglutide had symptom relief and improved fibrosis, compared to only 16.1% in the placebo group, demonstrating a significant therapeutic effect [8]. Group 4: Implications for Clinical Practice - The updated guidelines reflect the evolving landscape of scientific progress and clinical practice, providing physicians with tools to manage MASH and MASLD more effectively [9]. - The emergence of therapies like semaglutide offers patients and healthcare providers more options for improving liver health and overall well-being [9].